AIFA – PRALUENT (alirocumab): il registro di monitoraggio è aggiornato e convertito in piano terapeutico web-based
14/03/2024
Leggi
Breaking news
Relationship of device measured physical activity type and posture with cardiometabolic health markers: pooled dose-response associations from the Prospective Physical Activity, Sitting and Sleep Consortium
Ahmadi MN, Blodgett JM, Atkin AJ, et al.
Diabetologia. Pub. online 13 Mar 2024.
Leggi
AIFA – Classe di rimborsabilita’ A: formulazione mensile PRALUENT (alirocumab) 300 mg soluzione iniettabile in penna pre-riempita (1 penna) e 300 mg soluzione iniettabile in penna pre-riempita (3 penne)
14/03/2024
Leggi
AIFA – Repatha (evolocumab): il registro di monitoraggio è aggiornato e convertito in piano terapeutico web-based
14/03/2024
Leggi
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model
Helmink MAG, Hageman SHJ, Eliasson B, et al.
Diabetes Obes Metab. Pub. online 8 Mar 2024.
Leggi
The association between previous use of anti-obesity medication and semaglutide weight loss outcomes
Ghusn W, Fansa S, Anazco D, et al.
Diabetes Obes Metab. Pub. online 12 Mar 2024.
Leggi
Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada)
Jain AB, Reichert SM, Amadid H, et al.
Diabetes Obes Metab. Pub. online 11 Mar 2024.
Leggi
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
Brown DM, Boyer DS, Do DV, et al.
Lancet. 2024;S0140-6736(23)02577-1.
Leggi
Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis
Zhao H, Wu Y, Xie Y, et al.
Diabetes Obes Metab. Pub. online 11 Mar 2024.
Leggi
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
Cao L, An Y, Liu H, et al.
BMC Med. 2024;22(1):101.
Leggi